Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Soriano, F.
Right arrow Articles by Bryskier, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soriano, F.
Right arrow Articles by Bryskier, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 42, 647-649, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens

F Soriano, R Fernandez-Roblas, R Calvo, G Garcia-Calvo, M Pardeiro and A Bryskier
Department of Medical Microbiology, Fundacion Jimenez Diaz, Madrid, Spain. fsoriano@microb.net

We studied the in-vitro activity of HMR 3004 (RU 64004), a new ketolide, against 161 clinical isolates of Corynebacterium spp. including isolates resistant to erythromycin A, josamycin and lincomycin. HMR 3004 was active against all erythromycin A-sensitive isolates as well as against 75.8% and 45.4% of erythromycin A- intermediate and -resistant isolates, respectively. In contrast, HMR 3004 was active against 40 (46.5%) of 86 isolates resistant to erythromycin A, josamycin and lincomycin as well as against two isolates that were resistant to erythromycin A and lincomycin but not resistant (i.e. susceptible or intermediate) to josamycin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. S. Jacks, S. Giguere, and A. Nguyen
In Vitro Susceptibilities of Rhodococcus equi and Other Common Equine Pathogens to Azithromycin, Clarithromycin, and 20 Other Antimicrobials
Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1742 - 1745.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Fernandez-Roblas, R. Calvo, J. Esteban, A. Bryskier, and F. Soriano
The bactericidal activities of HMR 3004, HMR 3647 and erythromycin against Gram-positive bacilli and development of resistance
J. Antimicrob. Chemother., February 1, 1999; 43(2): 285 - 289.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.